TLR4 and chronic kidney disease: Additionally, protein expression of RANKL, a downstream target of the NF-κB signaling pathway activated by TLR4, was higher due to both CKD and oxycodone treatment resulting in nearly ~ 2.7-fold higher osteocyte RANKL in adenine–oxycodone-treated mice vs. control saline-treated mice.